Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

It is better to be in a clinical trial than not: lessons learnt from clinical neurology--the management of acute multiple sclerosis relapses.
Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection-a case report.
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Generic Midamor
Genzyme’s Lemtrada™ approved in Australia for treatment of multiple sclerosis
Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with interferon-beta-1b: a case report.
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.
Treatment of multiple sclerosis with anti-CD20 antibodies.
Cognitive impairment and cortical degeneration in neuromyelitis optica.
Cranial neuropathies in multiple sclerosis defined by magnetic resonance imaging and fludeoxyglucose f 18 positron emission tomography.
Flow cytometric analysis of cerebrospinal fluid samples and its usefulness in routine clinical practice.
2-Methoxyestradiol inhibits experimental autoimmune encephalomyelitis through suppression of immune cell activation.
Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010.
Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel.
Dopaminergic Modulation of CD4+CD25 Regulatory T Lymphocytes in Multiple Sclerosis Patients during Interferon-β Therapy.
Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects.
Multiple sclerosis.
Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP.
Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis
Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases.
Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.
LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex.
Confounding in association studies: month of birth and multiple sclerosis.
The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment.

Pages